Surmodics Statistics
Total Valuation
Surmodics has a market cap or net worth of $377.11 million. The enterprise value is $371.38 million.
| Market Cap | 377.11M |
| Enterprise Value | 371.38M |
Important Dates
The next estimated earnings date is Friday, May 3, 2024, before market open.
| Earnings Date | May 3, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Surmodics has 14.24 million shares outstanding. The number of shares has increased by 0.85% in one year.
| Shares Outstanding | 14.24M |
| Shares Change (YoY) | +0.85% |
| Shares Change (QoQ) | +0.27% |
| Owned by Insiders (%) | 3.75% |
| Owned by Institutions (%) | 91.43% |
| Float | 10.61M |
Valuation Ratios
The trailing PE ratio is 67.92 and the forward PE ratio is 81.97. Surmodics's PEG ratio is 3.90.
| PE Ratio | 67.92 |
| Forward PE | 81.97 |
| PS Ratio | 2.73 |
| Forward PS | 3.01 |
| PB Ratio | 3.09 |
| P/FCF Ratio | 38.23 |
| PEG Ratio | 3.90 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 16.33, with an EV/FCF ratio of 37.65.
| EV / Earnings | 67.27 |
| EV / Sales | 2.69 |
| EV / EBITDA | 16.33 |
| EV / EBIT | 27.86 |
| EV / FCF | 37.65 |
Financial Position
The company has a current ratio of 4.84, with a Debt / Equity ratio of 0.24.
| Current Ratio | 4.84 |
| Quick Ratio | 2.92 |
| Debt / Equity | 0.24 |
| Debt / EBITDA | 1.29 |
| Debt / FCF | 2.99 |
| Interest Coverage | 3.75 |
Financial Efficiency
Return on equity (ROE) is 4.80% and return on invested capital (ROIC) is 4.49%.
| Return on Equity (ROE) | 4.80% |
| Return on Assets (ROA) | 3.10% |
| Return on Capital (ROIC) | 4.49% |
| Revenue Per Employee | $367,561 |
| Profits Per Employee | $14,684 |
| Employee Count | 376 |
| Asset Turnover | 0.77 |
| Inventory Turnover | 2.10 |
Taxes
In the past 12 months, Surmodics has paid $4.25 million in taxes.
| Income Tax | 4.25M |
| Effective Tax Rate | 43.50% |
Stock Price Statistics
The stock price has increased by +12.53% in the last 52 weeks. The beta is 1.02, so Surmodics's price volatility has been similar to the market average.
| Beta (1Y) | 1.02 |
| 52-Week Price Change | +12.53% |
| 50-Day Moving Average | 29.50 |
| 200-Day Moving Average | 32.48 |
| Relative Strength Index (RSI) | 36.54 |
| Average Volume (30 Days) | 62,035 |
Short Selling Information
The latest short interest is 446,981, so 3.14% of the outstanding shares have been sold short.
| Short Interest | 446,981 |
| Short Previous Month | 441,064 |
| Short % of Shares Out | 3.14% |
| Short % of Float | 4.21% |
| Short Ratio (days to cover) | 10.91 |
Income Statement
In the last 12 months, Surmodics had revenue of $138.20 million and earned $5.52 million in profits. Earnings per share was $0.39.
| Revenue | 138.20M |
| Gross Profit | 109.70M |
| Operating Income | 12.06M |
| Pretax Income | 9.77M |
| Net Income | 5.52M |
| EBITDA | 22.74M |
| EBIT | 13.33M |
| Earnings Per Share (EPS) | $0.39 |
Balance Sheet
The company has $35.17 million in cash and $29.44 million in debt, giving a net cash position of $5.73 million or $0.40 per share.
| Cash & Cash Equivalents | 35.17M |
| Total Debt | 29.44M |
| Net Cash | 5.73M |
| Net Cash Per Share | $0.40 |
| Equity / Book Value | 122.15M |
| Book Value Per Share | 8.58 |
| Working Capital | 63.33M |
Cash Flow
In the last 12 months, operating cash flow was $12.52 million and capital expenditures -$2.66 million, giving a free cash flow of $9.86 million.
| Operating Cash Flow | 12.52M |
| Capital Expenditures | -2.66M |
| Free Cash Flow | 9.86M |
| FCF Per Share | $0.70 |
Margins
Gross margin is 79.38%, with operating and profit margins of 8.72% and 3.99%.
| Gross Margin | 79.38% |
| Operating Margin | 8.72% |
| Pretax Margin | 7.07% |
| Profit Margin | 3.99% |
| EBITDA Margin | 16.45% |
| EBIT Margin | 9.65% |
| FCF Margin | 7.14% |
Dividends & Yields
Surmodics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.85% |
| Shareholder Yield | -0.85% |
| Earnings Yield | 1.46% |
| FCF Yield | 2.62% |
Analyst Forecast
The average price target for Surmodics is $59.00, which is 122.73% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $59.00 |
| Price Target Difference | 122.73% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on December 7, 2000. It was a forward split with a ratio of 2:1.
| Last Split Date | Dec 7, 2000 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
Surmodics has an Altman Z-Score of 6 and a Piotroski F-Score of 8.
| Altman Z-Score | 6 |
| Piotroski F-Score | 8 |